Co-Authors
This is a "connection" page, showing publications co-authored by Benjamin Derman and Jennifer Cooperrider.
Connection Strength
1.904
-
Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant. Hemasphere. 2025 Aug; 9(8):e70186.
Score: 0.240
-
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood Adv. 2025 Jul 22; 9(14):3613-3616.
Score: 0.238
-
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma. Leukemia. 2025 Sep; 39(9):2285-2288.
Score: 0.238
-
Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma. Blood Cancer J. 2025 Mar 28; 15(1):47.
Score: 0.233
-
Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma. EJHaem. 2024 Dec; 5(6):1260-1264.
Score: 0.226
-
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 10 07; 14(1):170.
Score: 0.226
-
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood. 2024 08 29; 144(9):955-963.
Score: 0.224
-
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
Score: 0.220
-
Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma. Blood Neoplasia. 2025 Nov; 2(4):100124.
Score: 0.059